Deal facts
- Buyer
- Novacyt Holdings UK Limited
- Target
- Southern Cross Diagnostics Pty Ltd
- Deal value
- Not disclosed
- Announced
- 2 March 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- Australia
- Consideration
- Not stated
Sources
Novacyt Holdings UK Limited has agreed to acquire Southern Cross Diagnostics Pty Ltd in a strategic acquisition within the molecular diagnostics sector. The transaction was announced and completed on 2 March 2026, with the target operating out of Australia. The deal value and specific consideration terms were not disclosed to the public at the time of the announcement.
This acquisition brings the Australian diagnostic business under the ownership of the UK-based parent company, expanding its presence in the Southern Hemisphere. The integration of Southern Cross Diagnostics into the Novacyt group marks a significant step for the buyer in the molecular diagnostics field. The transaction is now complete following the successful closing on the announced date.
Weekly digest
Join Exit Mode Insider
Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.
Join Exit Mode Insider, £12/moDeal timeline
1 update- CompletedClosed
Novacyt Holdings UK Limited to acquire Southern Cross Diagnostics Pty Ltd
{ "headline": "Completion of Acquisition", "issuer": "Novacyt S.A. (CDI) (NCYT)", "announcement_date": "2026-03-02T07:00:00", "category_code": "Completion of Acquisition", "body": "Disclaimer* \n\n \n\n \n\n Novacyt S.A. \n\n (\"Novacyt\", the \"Company\" or the \"Group\") \n\n \n\n Completion of Acquisition \n\n \n\n Paris, France, and Manchester, UK - 2 March 2026 - Novacyt S.A.
LSE RNS
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.
Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.
- Buyer
- Shuttle Pharmaceuticals Holdings, Inc.
- Target
- United Dogecoin Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MedPal AI plc to acquire Remedi Solutions Limited
MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.
- Buyer
- MedPal AI plc
- Target
- Remedi Solutions Limited
- Deal value
- GBP 310,000
- Deal type
- strategic acquisition
BIOMARIN PHARMACEUTICAL INC to acquire Amicus
BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.
- Buyer
- BIOMARIN PHARMACEUTICAL INC
- Target
- Amicus
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.
- Buyer
- Telomir Pharmaceuticals, Inc.
- Target
- TELI Pharmaceuticals, Inc.
- Deal value
- USD 34,389,710
- Deal type
- strategic acquisition
GSK plc to acquire 35Pharma Inc.
GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…
- Buyer
- GSK plc
- Target
- 35Pharma Inc.
- Deal value
- USD 950,000,000
- Deal type
- strategic acquisition
Buyer history
Novacyt Holdings UK Limited
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive